Abstract:Abstract Background Although immune checkpoint blockade has emerged as a novel promising strategy for triple-negative breast cancer (TNBC), many patients fail response or acquire resistance to current agents. Consequently, our focus need to shift toward alternative inhibitory targets, predictor for responsiveness, and immune suppressive mechanisms. Methods In this study, we performed systematic bioinformatics analyses to identify PPP2R2B as a robust tumor suppressor in TNBC. Meanwhile, breast cancer progression cell line model was applied in our research. Quantitative real-time PCR assay (Q-PCR) was carried out to assess the role of PPP2R2B in the onset and progression of breast cancer. Furthermore, we validated the effect of PPP2R2B on immune activity via in vitro experiments based on macrophages. To further decipher the roles of PPP2R2B in TNBC, we investigated the transcriptome level, genomic profiles, and its clinical prognostic value. Results In TNBC tissues, PPP2R2B expression was significantly downregulated compared to normal breast tissues. Kaplan‐Meier survival analysis revealed that patients with low PPP2R2B expression had shorter survival time than those with high PPP2R2B expression. Q-PCR analysis suggested that PPP2R2B downregulation could play a key role in breast-cancer initiation and progression. Additionally, our findings showed that PPP2R2B was positively related with CD8 T cells, CD4 Th1 helper cells, and M1 macrophages, but negatively related with M2 macrophages. Subsequent results identified that PPP2R2B was strongly related with immune inhibitor genes (GZMA, PRF1, and IFNG), which could improve T lymphocytes antitumor function and restrict immune evasion. Meanwhile, T cell receptor signaling pathway and antigen processing and presentation signaling pathway were significantly suppressed in low PPP2R2B expression group. Afterwards, distinct subgroups based on PPP2R2B expression exhibited several unique features in somatic mutations, copy numbers alterations, extent of copy number burden, and promoter methylation level. Conclusion Our results indicated that PPP2R2B could serve as a promising biomarker for TNBC, and help predict immunotherapeutic response and guide personalized strategies in TNBC treatment.

PD-L1-mediated Immune Evasion in Triple-Negative Breast Cancer is Linked to the Loss of ZNF652

NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer

High Pd-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes And Leads To Good Clinical Outcomes In Chinese Triple Negative Breast Cancer Patients

FEZF2 inhibits the growth of triple-negative breast cancer cells through EZH2/PD-L1 and enhances anti-tumor immunity in vivo

Oncogenic HJURP is driven by P53/ E2F1/FOXM1-axis regulated enhancer and potentiates TNBC proliferation and invasion

Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients

PPP2R2B downregulation is associated with immune evasion and predicts poor clinical outcomes in triple-negative breast cancer

PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression

SHP-2-Mediated Upregulation of ZEB1 Is Important for PDGF-B-Induced Cell Proliferation and Metastatic Phenotype in Triple Negative Breast Cancer

Genomic Alterations Affecting Tumor-Infiltrating Lymphocytes and PD-L1 Expression Patterns in Triple-Negative Breast Cancer.

ZNF133 is a Potent Suppressor in Breast Carcinogenesis Through Dampening L1CAM, a Driver for Tumor Progression

ZNF652 exerts a tumor suppressor role in lung cancer by transcriptionally downregulating cyclin D3

p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target

UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer

ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer

Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model

Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer

PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy

ZNF133 is a potent suppressor in breast carcinogenesis through dampening L1CAM, a driver for tumor cell invasion

Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer

Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression